Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) maintains global leadership in blood safety through its INTERCEPT Blood System, a pathogen inactivation platform protecting transfusion medicine worldwide. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical advancements, and operational developments.
Access timely reports on FDA clearances, European CE marks, and partnerships with blood centers across 40+ countries. Track progress in platelet and plasma treatment adoption, red blood cell system trials, and international expansion efforts. Our curated news collection ensures you never miss critical updates about this biomedical innovator.
Key coverage areas include quarterly financial results analysis, peer-reviewed study publications, manufacturing capacity expansions, and strategic collaborations with global health organizations. All content is verified through primary sources including company filings and official statements.
Bookmark this page for streamlined access to CERS developments impacting transfusion safety standards. Combine real-time alerts with historical context to understand Cerus' role in combating emerging bloodborne pathogens through cutting-edge nucleic acid targeting technology.
Cerus Corporation (Nasdaq: CERS) announced a significant recommendation from the German National Blood Advisory Committee (AK Blut) advocating for pathogen inactivation (PI) measures, including INTERCEPT®, to enhance platelet transfusion safety.
The recommendation highlights that while current safeguards have reduced transfusion-transmitted bacterial infections (TTBI), risks remain with approximately 5 clinical cases per million transfusions, and potentially up to 1,300 contaminated units per million. Germany produces over 600,000 platelet doses annually, the highest in Europe.
Key recommendations include treating platelet units with PI or validated bacterial screening, extending PI-treated platelet shelf life to seven days, limiting untreated platelets to three days, and adjusting reimbursement rates to cover PI treatment costs.
Cerus Corporation (Nasdaq: CERS) announced its upcoming participation in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 10:55 A.M. ET.
Investors can access the live webcast through the Events and Presentations section on ir.cerus.com. A replay of the presentation will remain available for 30 days following the event.
Cerus Corporation (Nasdaq:CERS) reported strong Q2 2025 financial results with total revenue of $60.1 million, including record product revenue of $52.4 million, up 16% year-over-year. The company's INTERCEPT Fibrinogen Complex (IFC) revenue surged to $5.6 million from $2.0 million in the prior year.
Despite posting a net loss of $5.7 million, Cerus achieved positive non-GAAP adjusted EBITDA of $0.9 million. The company's cash position stood at $78.0 million as of June 30, 2025. Given strong performance, Cerus raised its full-year 2025 product revenue guidance to $200-203 million, with IFC revenue expected between $16-18 million.
Notable progress includes advancement in the European regulatory review of INTERCEPT Blood System for Red Blood Cells and a $7.2 million Department of Defense funding for lyophilized IFC development.
Cerus Corporation (Nasdaq: CERS) has scheduled the release of its second quarter 2025 financial results for Tuesday, August 5, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET to discuss financial results and provide business updates.
Investors can access the live webcast and presentation slides through Cerus' Investor Relations website. A replay will be available approximately three hours after the call until August 26, 2025.
Cerus Corporation (Nasdaq: CERS) has secured an additional $7.2 million contract amendment from the U.S. Department of Defense (DoD) to advance the development of lyophilized INTERCEPT Fibrinogen Complex (LyoIFC) for treating trauma-related bleeding. This supplements their existing $18 million DoD contract for developing room-temperature, shelf-stable LyoIFC.
The new funding will support the CRYO-FIRST study, a 320-patient randomized trial comparing pre-thawed IFC to conventional cryoprecipitated antihemophilic factor in trauma patients with hemorrhagic shock. The study aims to evaluate the effectiveness of early fibrinogen administration in trauma patients and will begin enrollment in early 2026.
Since receiving initial DoD funding in November 2022, Cerus has achieved key milestones including FDA pathway discussions, successful process scale-up, and prototype delivery to the DoD.
Cerus Corporation (Nasdaq: CERS) announced progress in its European regulatory review for the INTERCEPT Red Blood Cells (RBC) system. The company's Notified Body, TÜV-SÜD, has completed reviewing the clinical module of the CE Mark submission and transferred information to the Czech Republic's State Institute for Drug Control (SÚKL).
The clinical module includes positive results from the U.S. Phase 3 ReCePI trial, expanding the CE Mark submission to cover all patient indications for RBC transfusion. SÚKL will now review the API module before TÜV-SÜD conducts manufacturing facility audits for final CE Mark decision.
Cerus Corporation (CERS) will present clinical data for its INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan from May 31 to June 4, 2025. The presentations will highlight data on the system's applications for platelets, plasma, cryoprecipitated fibrinogen complex, and red blood cells.
Key presentations include positive results from the Phase 3 ReCePI study in red blood cells, INTERCEPT treated cold stored platelets, and effective inactivation of California encephalitis virus. The event features a Cerus-sponsored symposium focusing on INTERCEPT's impact on adverse events, platelet use, and inventory management in France, along with its safety in neonates.
Multiple oral and poster presentations will cover topics including cold-stored platelet concentrates, reduced hemoglobin use in cardiac surgery, and pathogen reduction effectiveness.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
